Built-in Effort Tracking Streamlines Resource Allocation and Budgeting for Users of Allegro CTMS@Site
The summer release of Allegro [email protected]®, from Forte Research Systems, Inc., is full of new features that allow sites to operate more dynamically and efficiently. The clinical trial management system has new calendar options for managing staff time and expanded report choices. In addition, the summer release includes the feature of staff effort tracking.
The new functionality in Allegro [email protected] can help solve the problem of underestimating the number of hours staff spends on activities by allowing the site to track the staff time involved on any number of clinical trials, based on user-defined categories. Additionally, the staff management calendar feature grants selected site staff the opportunity to view schedules of other staff members from within the CTMS.
To set up a demonstration of Allegro [email protected] or to learn more, please contact Forte Research Systems.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
